Read as much as you want on BostonGlobe.com, anywhere and anytime, for just 99¢.

Around the Region

AVEO to cut 45 jobs, 17% of its staff

AVEO Oncology, a Cambridge company looking to develop a treatment for advanced kidney cancer, has embarked on a “strategic restructuring” that will cut 45 positions, or 17 percent of the workforce, as well as eliminate 30 open positions.

The reduction, unveiled Tuesday, is part of a program that is expected to save 100 million over the next three years, with $37 million in savings projected in 2013. After the restructuring, AVEO will have about 225 employees.

Continue reading below

The announcement was included in a press release about third-quarter earnings.

Total collaboration revenue for the quarter was $1 million, compared with $3.6 million for the third quarter of 2011. AVEO said its net loss was $30.1 million, or basic and diluted net loss per share of 69 cents, compared with a net loss of $23.8 million, or basic and diluted net loss per share of 55 cents, a year earlier.

In September, AVEO and the Japanese drug maker Astellas Pharma Inc. said they had submitted a new drug application to the Food and Drug Administration for tivozanib, a potential treatment for advanced kidney cancer.

AVEO said Tuesday that it is now seeking collaborators to help develop ficlatuzumab, another cancer drug candidate.

Loading comments...

You have reached the limit of 10 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week